{"id":6922,"date":"2019-01-24T16:21:18","date_gmt":"2019-01-24T16:21:18","guid":{"rendered":"https:\/\/oncopeptides.com.haus.se\/investors\/aktien\/nyemissioner\/nyemission-januari-2019\/"},"modified":"2026-03-19T15:47:33","modified_gmt":"2026-03-19T15:47:33","slug":"nyemission-januari-2019","status":"publish","type":"investors","link":"https:\/\/oncopeptides.com.haus.se\/sv\/investerare\/aktien\/nyemissioner\/nyemission-januari-2019\/","title":{"rendered":"Nyemission januari 2019"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"6922\" class=\"elementor elementor-6922 elementor-6841\" data-elementor-post-type=\"investors\">\n\t\t\t\t<style>\n                .elementor-element-f07da12{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-f07da12 e-flex e-con-boxed e-con e-parent\" data-id=\"f07da12\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<style>\n                .elementor-element-dbab357{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-dbab357 e-con-full haus-2-1 e-flex e-con e-child\" data-id=\"dbab357\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-b6da00d elementor-widget elementor-widget-heading\" data-id=\"b6da00d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">Nyemission<br><span style=\"color: var(--color-orange)\">januari 2019<\/span><\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-72365fe dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"72365fe\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-a120c67{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-a120c67 e-con-full e-flex e-con e-child\" data-id=\"a120c67\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2a2c081 elementor-widget elementor-widget-text-editor\" data-id=\"2a2c081\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h2>Oncopeptides har genomf\u00f6rt en riktad nyemission om cirka 546 miljoner kronor<\/h2>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5a011ba elementor-widget elementor-widget-text-editor\" data-id=\"5a011ba\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>24 januari 2019 \u2013 Regulatoriskt pressmeddelande<\/p><p>Oncopeptides AB meddelar att bolaget framg\u00e5ngsrikt har genomf\u00f6rt en riktad nyemission om cirka 546 miljoner kronor.<\/p><p>Styrelsen f\u00f6r Oncopeptides har, med st\u00f6d av det emissionsbemyndigande som l\u00e4mnades av \u00e5rsst\u00e4mman den 17 maj 2018, och enligt bolagets pressmeddelande den 23 januari 2019, beslutat om en riktad nyemission av 4 750 000 nya aktier (de &#8221;Nya Aktierna&#8221;) till en teckningskurs om 115 kronor per aktie (&#8221;Emissionen&#8221;), vilket inneb\u00e4r att bolaget kommer att erh\u00e5lla en bruttoemissionslikvid om cirka 546 miljoner kronor.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-81d4b76 elementor-widget elementor-widget-button\" data-id=\"81d4b76\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/oncopeptides.com.haus.se\/sv\/pressmeddelanden\/oncopeptides-har-genomfort-en-riktad-nyemission-om-cirka-546-miljoner-kronor\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">L\u00e4s pressmeddelandet<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-eadd8a8 dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"eadd8a8\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-b4be30e{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-b4be30e e-con-full e-flex e-con e-child\" data-id=\"b4be30e\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-8ab8f18 elementor-widget elementor-widget-text-editor\" data-id=\"8ab8f18\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h2>Oncopeptides avser att genomf\u00f6ra en riktad nyemission<\/h2>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-7e45d53 elementor-widget elementor-widget-text-editor\" data-id=\"7e45d53\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>23 januari 2019 \u2013 Regulatoriskt pressmeddelande<\/p><p>Oncopeptides AB meddelar sin avsikt att genomf\u00f6ra en riktad nyemission till svenska och internationella institutionella investerare (&#8221;Emissionen&#8221;). Bolaget har anlitat Jefferies International Limited, Carnegie Investment Bank AB (publ) och DNB Markets, en del av DNB Bank ASA, att agera Joint Bookrunners (&#8221;Joint Bookrunners&#8221;) i samband med Emissionen. <\/p><p>Teckningskursen och det totala antalet nya aktier i Emissionen (&#8221;Emissionsaktierna&#8221;) kommer att fastst\u00e4llas genom ett accelererat bookbuilding-f\u00f6rfarande (&#8221;Bookbuilding&#8221;). Det \u00e4r avsett att antalet nyemitterade aktier ska uppg\u00e5 till cirka 10 procent av det totala antalet aktier i bolaget. Bookbuilding kommer att p\u00e5b\u00f6rjas omedelbart efter detta meddelande.  <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3d05577 elementor-widget elementor-widget-button\" data-id=\"3d05577\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/oncopeptides.com.haus.se\/sv\/pressmeddelanden\/oncopeptides-avser-att-genomfora-en-riktad-nyemission\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">L\u00e4s pressmeddelandet<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"featured_media":0,"parent":5698,"menu_order":0,"template":"","meta":{"_acf_changed":false},"protected-content":[341],"class_list":["post-6922","investors","type-investors","status-publish","hentry","protected-content-show-disclaimer"],"acf":[],"_links":{"self":[{"href":"https:\/\/oncopeptides.com.haus.se\/sv\/wp-json\/wp\/v2\/investors\/6922","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oncopeptides.com.haus.se\/sv\/wp-json\/wp\/v2\/investors"}],"about":[{"href":"https:\/\/oncopeptides.com.haus.se\/sv\/wp-json\/wp\/v2\/types\/investors"}],"version-history":[{"count":1,"href":"https:\/\/oncopeptides.com.haus.se\/sv\/wp-json\/wp\/v2\/investors\/6922\/revisions"}],"predecessor-version":[{"id":6923,"href":"https:\/\/oncopeptides.com.haus.se\/sv\/wp-json\/wp\/v2\/investors\/6922\/revisions\/6923"}],"up":[{"embeddable":true,"href":"https:\/\/oncopeptides.com.haus.se\/sv\/wp-json\/wp\/v2\/investors\/5698"}],"wp:attachment":[{"href":"https:\/\/oncopeptides.com.haus.se\/sv\/wp-json\/wp\/v2\/media?parent=6922"}],"wp:term":[{"taxonomy":"protected-content","embeddable":true,"href":"https:\/\/oncopeptides.com.haus.se\/sv\/wp-json\/wp\/v2\/protected-content?post=6922"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}